Aytu Bioscience Inc (NASDAQ:AYTU)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued on Thursday. They currently have a $9.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 168.66% from the stock’s current price.
Separately, Rodman & Renshaw assumed coverage on shares of Aytu Bioscience in a research report on Monday. They issued a “buy” rating and a $9.00 price objective for the company.
Shares of Aytu Bioscience (NASDAQ:AYTU) remained flat at $3.35 during mid-day trading on Thursday. The company had a trading volume of 36 shares. The stock’s 50 day moving average price is $3.65 and its 200 day moving average price is $4.80. The company’s market capitalization is $16.98 million. Aytu Bioscience has a 1-year low of $3.01 and a 1-year high of $57.00.
Aytu Bioscience Company Profile
Aytu Bioscience, Inc, formerly Rosewind Corporation, is a healthcare company. The Company is focused on developing treatments for urological and related conditions. The Company’s pipeline of products includes Zertane, and Zertane and a phosphodiesterase type 5 (PDE-5). The Company is conducting Phase III clinical development for its lead therapeutic candidate Zertane, an orally disintegrating tablet (ODT) formulated for the treatment of premature ejaculation (PE).
Receive News & Ratings for Aytu Bioscience Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience Inc and related companies with MarketBeat.com's FREE daily email newsletter.